Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Septicemia | Case Report

Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report

Authors: Xiaohong Pan, Jiekun Xu, Lei Pan, Caihong Wang, Junke Qiu, Xiaqing Huang, Chenxi Yan, Minjie Mao

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Septic arthritis requires prompt diagnosis and treatments. Rare pathogens should be considered when patients respond poorly to the initial antibiotic treatments. Ureaplasma parvum is an opportunistic pathogen that commonly resides in the human urogenital tract. Its infection commonly causes hyperammonemia. Hyperammonemia from Ureaplasma parvum septic arthritis has never been reported previously.

Case presentation

A 65-year-old male presented with fever and left lower leg pain and swelling for more than ten days. Septic arthritis and sepsis were considered after laboratory tests and arthrocentesis. However, he responded poorly to the antibiotic treatments, including cefoperazone-sulbactam, imipenem-cilastatin, and linezolid. His mental status deteriorated rapidly with elevated blood ammonia levels with unremarkable liver function test and sonogram examination results. Despite the treatments with lactulose, L-ornithine L-aspartate, mannitol, and hemodialysis therapy to lower his ammonia level, his blood ammonia level remained persistently high. Finally, metagenomic sequencing of the left knee synovial fluid reported Ureaplasma parvum, which was considered to contribute to his hyperammonemia.

Conclusion

Ureaplasma parvum could cause septic arthritis with hyperammonemia. Genetic tests, such as polymerase chain reaction and next-generation sequencing techniques, could provide a sensitive and fast diagnosis of Ureaplasma parvum.
Literature
1.
go back to reference Ali R, Nagalli S. Hyperammonemia. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022. Ali R, Nagalli S. Hyperammonemia. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022.
2.
go back to reference Tantengco OAG, De Jesus FCC, Gampoy EFS, et al. Hyperammonemia syndrome associated with Ureaplasma spp. Infections in immunocompromised patients and transplant recipients: a systematic review and meta-analysis. Clin Transpl. 2021;35:e14334.CrossRef Tantengco OAG, De Jesus FCC, Gampoy EFS, et al. Hyperammonemia syndrome associated with Ureaplasma spp. Infections in immunocompromised patients and transplant recipients: a systematic review and meta-analysis. Clin Transpl. 2021;35:e14334.CrossRef
3.
go back to reference Sarier M, Kukul E. Classification of non-gonococcal urethritis: a review. Int Urol Nephrol. 2019;51:901–7.CrossRef Sarier M, Kukul E. Classification of non-gonococcal urethritis: a review. Int Urol Nephrol. 2019;51:901–7.CrossRef
4.
go back to reference Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem. 2014;67:73–150.CrossRef Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem. 2014;67:73–150.CrossRef
5.
go back to reference Kokkayil P, Dhawan B. Ureaplasma: current perspectives. Indian J Med Microbiol. 2015;33:205–14.CrossRef Kokkayil P, Dhawan B. Ureaplasma: current perspectives. Indian J Med Microbiol. 2015;33:205–14.CrossRef
6.
go back to reference Bharat A, Cunningham SA, Scott Budinger GR, et al. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med. 2015;7:284re283.CrossRef Bharat A, Cunningham SA, Scott Budinger GR, et al. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med. 2015;7:284re283.CrossRef
7.
go back to reference Roberts SC, Malik W, Ison MG. Hyperammonemia syndrome in immunosuppressed individuals. Curr Opin Infect Dis. 2022;35:262–8.CrossRef Roberts SC, Malik W, Ison MG. Hyperammonemia syndrome in immunosuppressed individuals. Curr Opin Infect Dis. 2022;35:262–8.CrossRef
9.
go back to reference Furr P, Taylor-Robinson D, Webster A. Mycoplasmas and ureaplasmas in patients with hypogammaglobulinaemia and their role in arthritis: microbiological observations over twenty years. Ann Rheum Dis. 1994;53:183–7.CrossRef Furr P, Taylor-Robinson D, Webster A. Mycoplasmas and ureaplasmas in patients with hypogammaglobulinaemia and their role in arthritis: microbiological observations over twenty years. Ann Rheum Dis. 1994;53:183–7.CrossRef
11.
go back to reference Lemoine L, Le Brun C, Maillot F, et al. Dual Ureaplasma parvum arthritis: a case report of U. parvum septic arthritis following contralateral reactive arthritis in an immunosuppressed patient. BMC Infect Dis. 2021;21:1117.CrossRef Lemoine L, Le Brun C, Maillot F, et al. Dual Ureaplasma parvum arthritis: a case report of U. parvum septic arthritis following contralateral reactive arthritis in an immunosuppressed patient. BMC Infect Dis. 2021;21:1117.CrossRef
12.
go back to reference Verhagen I, Oudenhoven H, van Welzen B, et al. Ureaplasma parvum bacterial arthritis of the elbow in a patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford). 2021;60:e17–8.CrossRef Verhagen I, Oudenhoven H, van Welzen B, et al. Ureaplasma parvum bacterial arthritis of the elbow in a patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford). 2021;60:e17–8.CrossRef
13.
go back to reference Farrell JJ, Larson JA, Akeson JW, et al. Ureaplasma parvum prosthetic joint infection detected by PCR. J Clin Microbiol. 2014;52:2248–50.CrossRef Farrell JJ, Larson JA, Akeson JW, et al. Ureaplasma parvum prosthetic joint infection detected by PCR. J Clin Microbiol. 2014;52:2248–50.CrossRef
14.
go back to reference Mahlouly J, Lhopitallier L, Suttels V, et al. Septic arthritis of the shoulder due to Ureaplasma urealyticum after emergency caesarean section: a case report. BMC Infect Dis. 2020;20:1–6.CrossRef Mahlouly J, Lhopitallier L, Suttels V, et al. Septic arthritis of the shoulder due to Ureaplasma urealyticum after emergency caesarean section: a case report. BMC Infect Dis. 2020;20:1–6.CrossRef
15.
go back to reference Vittecoq O, Favre S, Daragon A, et al. Molecular diagnosis of Ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis. Arthritis Rheum. 1997;40:2084–9.CrossRef Vittecoq O, Favre S, Daragon A, et al. Molecular diagnosis of Ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis. Arthritis Rheum. 1997;40:2084–9.CrossRef
16.
go back to reference Sethi S, Sharma M, Gill S. Septic arthritis due to Ureaplasma urealyticum. Indian Pediatr. 2000;37:552–4. Sethi S, Sharma M, Gill S. Septic arthritis due to Ureaplasma urealyticum. Indian Pediatr. 2000;37:552–4.
17.
go back to reference Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the european STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32:1845–51.CrossRef Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the european STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32:1845–51.CrossRef
19.
go back to reference Waites KB, Crabb D, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53:2139–41.CrossRef Waites KB, Crabb D, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53:2139–41.CrossRef
Metadata
Title
Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report
Authors
Xiaohong Pan
Jiekun Xu
Lei Pan
Caihong Wang
Junke Qiu
Xiaqing Huang
Chenxi Yan
Minjie Mao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07953-8

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine